Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Operations: 2023-2025

Historic Cash from Operations for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$38.9 million.

  • CG Oncology's Cash from Operations fell 144.32% to -$38.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$116.8 million, marking a year-over-year decrease of 60.66%. This contributed to the annual value of -$78.7 million for FY2024, which is 72.32% down from last year.
  • CG Oncology's Cash from Operations amounted to -$38.9 million in Q3 2025, which was down 39.23% from -$27.9 million recorded in Q2 2025.
  • CG Oncology's 5-year Cash from Operations high stood at -$8.0 million for Q1 2023, and its period low was -$38.9 million during Q3 2025.
  • Moreover, its 3-year median value for Cash from Operations was -$16.1 million (2024), whereas its average is -$20.0 million.
  • Data for CG Oncology's Cash from Operations shows a maximum YoY tumbled of 225.72% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Cash from Operations stood at -$14.6 million in 2023, then tumbled by 41.09% to -$20.7 million in 2024, then slumped by 144.32% to -$38.9 million in 2025.
  • Its last three reported values are -$38.9 million in Q3 2025, -$27.9 million for Q2 2025, and -$29.3 million during Q1 2025.